SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecular ...

Global Vaccine Adjuvants Market size is expected to be worth around USD 1289.0 Million by 2023 from USD 3,933.7 Million in 2032, growing at a CAGR of 13.6% The Research Segment Is The Fastest ...

R.F.K. Jr. and others have blamed the ingredient for allergies and other illnesses. Scientists say it actually bolsters the ...

Additionally, there is the adjuvant QS-21, used in several innovative vaccines against diseases, plus promising new vaccine and immunotherapy treatments in the oncology space. BSI is now using its ...

This category of vaccine adjuvant has dominated the literature on vaccine research in the last decade, and comprises the category of signal 2 facilitators, which include stranger and danger ...

We now have new knowledge for suggesting optimal strategies in using adjuvant for therapeutic cancer vaccines. Increasing interest is given to combinatorial approaches to augment immune T-cell ...

LEXINGTON, Mass.--(BUSINESS WIRE)--SaponiQx, a leader in next-generation saponin-based adjuvant discovery and a subsidiary of Agenus Inc., today announced the publication of their latest preclinical ...

Dr. Sharifpour and his team discovered that SPEV has enormous potential as a novel class of vaccine adjuvant (substances added to vaccines to make them more effective) while conducting safe ...